PT-141 — generic name bremelanotide — is the peptide behind Vyleesi, a drug the FDA approved back in 2019 for low sexual desire in premenopausal women. What makes it unusual is where it works: not on blood flow like Viagra, but in the brain, on the melanocortin system that helps drive desire itself.
That is why it is one of the few compounds in this space actually studied in women rather than borrowed from men’s medicine. The trial effect was real but modest, the side effects are worth knowing, and — as always — the research compound sold by peptide suppliers is not the approved drug. Here is the honest rundown.
What PT-141 is
PT-141 is the research name for bremelanotide, a synthetic peptide that activates melanocortin receptors in the brain. It began life in research on a tanning peptide and took an unexpected turn when subjects reported effects on sexual arousal. That observation eventually led to Vyleesi, which the FDA approved in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — low desire that is distressing and not explained by another cause.
It is one of only a small number of treatments ever approved specifically for female sexual desire, which is a big part of why “PT-141 for women” draws so much search interest. For how it sits next to other desire and hormone peptides, see kisspeptin vs HCG vs PT-141.
How it works: brain, not plumbing
This is the key distinction. Drugs like Viagra and Cialis are vascular — they improve blood flow, which addresses the mechanics of arousal but does nothing for desire. PT-141 works upstream, in the central nervous system, on the melanocortin-4 pathway involved in sexual motivation. In other words, it targets wanting, not just the physical response.
That makes it conceptually suited to women with low desire, where the problem is often the drive itself rather than blood flow. It is used on an as-needed basis ahead of anticipated activity rather than taken daily — one of the practical differences from the other approved female-desire drug, Addyi.
Viagra fixes the plumbing. PT-141 works on the wanting. That is why it is one of the only desire drugs ever studied specifically in women.The one-line explanation of melanocortin agonists
What the trials showed in women
Approval rested on two large Phase 3 trials known together as RECONNECT, which enrolled premenopausal women with HSDD. Compared with placebo, bremelanotide produced statistically significant improvements in two things that matter: sexual desire (measured on a validated questionnaire) and the distress associated with low desire.
The honest framing, which the better clinicians always add: the average effect was real but modest. This is not a switch that flips desire back on; it is a measurable nudge that helped a meaningful share of women enough to be worth it, while others saw little benefit. That is typical for this difficult area of medicine, and it is a more useful expectation than the hype.
Who it was actually studied in
Precision matters here. Vyleesi was studied and approved in premenopausal women with acquired, generalized HSDD — meaning desire that was once normal and then dropped across all situations, causing distress. It was not established in postmenopausal women, and it is not a treatment for arousal or orgasm problems, relationship issues, or low desire caused by another medication or condition. Those distinctions are exactly what a clinician sorts out before considering it.
Side effects
The most common by far is nausea, which affected a large share of women in trials, especially with the first dose. Other reported effects include flushing, headache, and injection-site reactions. Two worth flagging specifically: a transient rise in blood pressure with a dip in heart rate after dosing (which is why it is not for people with uncontrolled high blood pressure or cardiovascular disease), and focal hyperpigmentation — darkening of skin or gums — which can occur with repeated use, more so in people with darker skin or who dose frequently.
Vyleesi (bremelanotide) is a prescription medicine, and whether it is appropriate — and at what dose — is a decision for a clinician, particularly given its blood-pressure effects. This article does not provide dosing guidance. PT-141 sold as a research compound is not the approved drug.
PT-141 vs Viagra vs Addyi
| PT-141 (Vyleesi) | Addyi (flibanserin) | Viagra (sildenafil) | |
|---|---|---|---|
| Target | Brain desire pathway (melanocortin) | Brain serotonin/dopamine balance | Blood flow (vascular) |
| Addresses | Low desire | Low desire | Physical arousal / erection |
| Approved for women? | Yes (premenopausal HSDD) | Yes (premenopausal HSDD) | No |
| How used | As needed before activity | Daily | As needed before activity |
| Alcohol | Limit | Avoid (significant interaction) | Caution |
The short version: PT-141 and Addyi both target desire but in different ways and on different schedules; Viagra targets a different problem entirely. None of them is a universal fix, and all are medical decisions.
The research-compound angle
PT-141 is widely sold as a research peptide — at TrueLabs it is listed as PT-141. The distinction is the same one that runs through this whole category: the research compound is a raw material for in vitro and laboratory study, not the approved, dose-formulated Vyleesi auto-injector, and it carries no verified human dose, sterile formulation or regulatory oversight. The trial results above describe the pharmaceutical drug used under medical supervision. For related research background, see what is PT-141 and PT-141 side effects.
PT-141-for-women myths
“Myth: PT-141 is just female Viagra.”
No. Viagra works on blood flow; PT-141 works on the brain’s desire pathway. They address different problems.
“Myth: It dramatically boosts libido for everyone.”
Trial effects were real but modest. It helped a meaningful share of women noticeably; others saw little. Expect a nudge, not a switch.
“Myth: It works for postmenopausal women too.”
It was studied and approved in premenopausal women. Its effect in postmenopausal women is not established.
“Myth: The research peptide is the same as Vyleesi.”
It is not — no verified dose, sterile formulation or approval. The approved drug is the regulated version.
For researchers
TrueLabs supplies PT-141 from $45 and Kisspeptin from $34 — two of the main peptides in the sexual-function and reproductive-signalling literature — in CAD for in vitro and laboratory research only. Before ordering, see how to read a peptide COA and the COA library.
FAQ
Tap a question to reveal the answer.
What is PT-141 used for in women?
As the drug Vyleesi (bremelanotide), it is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women — distressing low desire not explained by another cause. It targets the brain’s desire pathway.
How is PT-141 different from Viagra?
Viagra improves blood flow to address the mechanics of arousal. PT-141 works centrally on the melanocortin system involved in desire itself. They treat different problems.
Does PT-141 actually increase female libido?
In the RECONNECT trials it produced statistically significant but modest improvements in desire and in the distress around low desire. It helped a meaningful share of women; others saw little benefit.
Is PT-141 approved for women?
Yes, as Vyleesi, approved by the FDA in 2019 for premenopausal women with HSDD. It was not established in postmenopausal women.
What are the side effects?
Nausea is the most common, especially with the first dose. Others include flushing, headache, a transient blood-pressure rise, and skin or gum darkening with repeated use.
How is it taken?
As an as-needed injection before anticipated activity rather than daily. Specific dosing is a medical matter and not covered here.
Can postmenopausal women use PT-141?
Its effect in postmenopausal women is not established, and approval was limited to premenopausal women. That is a question for a clinician.
Is research PT-141 the same as Vyleesi?
No. Research PT-141 (such as TrueLabs’ listing) is a raw compound for laboratory use, not the approved, dose-formulated drug, and carries no verified dose, formulation or oversight.
Related reading
- What is PT-141?
- Kisspeptin vs HCG vs PT-141
- PT-141 side effects
- Erectile dysfunction research in Canada
- Low testosterone in Canada
References
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (RECONNECT). Obstet Gynecol. 2019;134(5):899-908.
- Clinical trials RECONNECT. NCT02333071 and NCT02338960.
- European Pharmaceutical Review. FDA approves treatment for sexual dysfunction in premenopausal women (bremelanotide), 2019. EPR
This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.